Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Amortization of Deferred Charges (2024 - 2025)

Historic Amortization of Deferred Charges for TriSalus Life Sciences (TLSIW) over the last 2 years, with Q3 2025 value amounting to $308000.0.

  • TriSalus Life Sciences' Amortization of Deferred Charges rose 8443.11% to $308000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $978000.0, marking a year-over-year increase of 12534.56%. This contributed to the annual value of $612000.0 for FY2024, which is N/A changed from last year.
  • TriSalus Life Sciences' Amortization of Deferred Charges amounted to $308000.0 in Q3 2025, which was up 8443.11% from $257000.0 recorded in Q2 2025.
  • TriSalus Life Sciences' Amortization of Deferred Charges' 5-year high stood at $308000.0 during Q3 2025, with a 5-year trough of $167000.0 in Q3 2024.